<?xml version="1.0" encoding="UTF-8"?>
<p>The presence of 
 <italic>TP53</italic> aberrations [del(17p) or 
 <italic>TP53</italic> mutation] is strongly associated with chemotherapy refractoriness, early relapse,
 <sup>
  <xref rid="b13-1040797" ref-type="bibr">13</xref>,
  <xref rid="b14-1040797" ref-type="bibr">14</xref>
 </sup> and, until recently, a very dismal prognosis.
 <sup>
  <xref rid="b14-1040797" ref-type="bibr">14</xref>–
  <xref rid="b16-1040797" ref-type="bibr">16</xref>
 </sup> Hence, evaluation of 
 <italic>TP53</italic> status is strongly recommended before treatment initiation. Brutons's tyrosine kinase (BTK) inhibitor ibrutinib
 <sup>
  <xref rid="b17-1040797" ref-type="bibr">17</xref>–
  <xref rid="b19-1040797" ref-type="bibr">19</xref>
 </sup> has offered new options both for these patients and for relapsed/refractory CLL,
 <sup>
  <xref rid="b20-1040797" ref-type="bibr">20</xref>
 </sup> with an ORR of 85% reported,
 <sup>
  <xref rid="b17-1040797" ref-type="bibr">17</xref>,
  <xref rid="b18-1040797" ref-type="bibr">18</xref>
 </sup> and is considered the best available option for patients with 
 <italic>TP53</italic> disruptions.
 <sup>
  <xref rid="b3-1040797" ref-type="bibr">3</xref>,
  <xref rid="b20-1040797" ref-type="bibr">20</xref>,
  <xref rid="b21-1040797" ref-type="bibr">21</xref>
 </sup> New treatments are costly and frequently accepted by regulatory agencies based on trials conducted in selected groups of patients with PFS, not OS, as end point. Hence, long-term results, including OS estimates, in real-life treated patients are important to determine the optimal therapy for patients with CLL.
 <sup>
  <xref rid="b22-1040797" ref-type="bibr">22</xref>
 </sup>
</p>
